3 news items
InflaRx Hosts R&D Event Highlighting the Promise of INF904
IFRX
5 Jun 24
additional safety and pharmacokinetic (PK) data, and showing meaningful clinical benefit
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
IFRX
21 May 24
. Safety was also assessed. The point estimate for 28-day all-cause mortality was 6.3% in the vilobelimab plus tocilizumab
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
IFRX
8 May 24
trial enrolling CSU and HS patients is expected to begin by the end of 2024 and to assess safety, as well as PK and PD parameters. InflaRx anticipates
- Prev
- 1
- Next